Click here to view online. Add this email to your safelist.

AstraZeneca logo

AstraZeneca divestment of Movantik to RedHill Biopharma completed

2 April 2020

AstraZeneca has completed the previously communicated agreement to sublicense its global rights to Movantik (naloxegol), excluding Europe, Canada and Israel, to RedHill Biopharma (RedHill).

Read more  Read more

RSS Feed  RSS Feed Twitter  Follow us on Twitter LinkedIn  Follow us on LinkedIn
Legal notice and Terms of Use Privacy policy Cookie policy Site map © AstraZeneca 2020

For more information please visit astrazeneca.com.

If you would like to unsubscribe please click here.